by Advancements in Diabetes Devices And Drugs
Diabetes management has progressed significantly over the past few decades through advancements in devices and drugs. Continuous glucose monitors, insulin pumps, and new insulin formulations allow people to better control their blood sugar levels. Here is an overview of some of the recent developments.
Continuous Glucose Diabetes Devices And Drugs
Continuous glucose monitoring (CGM) systems use a small sensor inserted under the skin to continuously monitor glucose levels in interstitial fluid. The sensor transmits readings to a receiver or smartphone every few minutes. This provides near real-time glucose readings without the need for fingersticks.
Some key benefits of CGM systems include the ability to see trends and how foods, medication, and activity impact blood sugar over time. Diabetes Devices And Drugs can also alert users when glucose levels go above or below set ranges. The Dexcom G6 and Medtronic Guardian Connect are two popular integrated CGM and insulin pump systems.
Insulin Pumps
Insulin pumps are devices that deliver insulin doses continuously through a small tube inserted under the skin. They allow for flexible, automated insulin delivery instead of multiple daily injections.
Newer “hybrid closed loop” pumps like the Tandem t:slim X2 with Control-IQ technology and Medtronic MiniMed 770G uses CGM readings to automatically adjust insulin dosing. This greatly reduces the risk of hypoglycemia. Omnipod 5, expected to launch later this year, will be the first tubeless insulin pump with automatic delivery based on CGM.
Premixed and Concentrated Insulin
Several new insulin formulations provide options for tighter glycemic control or greater flexibility. Premixed insulins like NovoLog Mix 70/30 and Humalog Mix 75/25 contain a fixed ratio of rapid and long-acting insulin in one vial.
Concentrated U-500 insulin contains 5 times the concentration of U-100 insulin, allowing a smaller volume to match higher insulin needs. Insulin glargine U-300 has a flatter profile than older glargine products, lowering risk of hypoglycemia. Fiasp is an ultra-fast acting insulin that reaches peak action within one hour.
Artificial Pancreas Systems
The ultimate goal for many researchers is to develop an “artificial pancreas” – a fully automated system that closely mimics the function of a healthy pancreas. This would involve combining a CGM, insulin pump, and control algorithm into one user-friendly device.
While an “off-the-shelf” artificial pancreas is likely still years away, selected patients have been able to trial prototype closed loop systems in research settings. The FDA has also approved some products with automated insulin delivery capabilities, like the aforementioned Tandem and Medtronic pumps, bringing closed loop functionality closer to wide commercial availability.
Smart Technology Integration
Diabetes management technology is also integrating with smartphones and other devices. Popular CGM apps like Dexcom CLARITY allow uploading readings to the cloud for easy sharing. Insulin pumps increasingly feature Bluetooth connectivity and companion apps for remote bolusing, settings changes, and data displays.
Voice assistants are also entering the diabetes space. Apps like MySugr, Glucose Buddy, and IBM Watson Assistant use virtual assistants powered by Amazon Alexa or Google Assistant to provide personalized guidance on dosing, nutrition, and handling highs and lows. As technology continues advancing, connectivity and automation will further streamline diabetes care.
Diabetes medicines: Final Summary
diabetes management tools have made tremendous strides in recent years towards precision, automation, connectivity, and flexibility. Continuous glucose monitors provide real-time insight, while hybrid closed loop insulin pumps are pioneers in automation. Concentrated and novel insulin formulations offer options for tighter control or convenience. Integrated systems and smart devices seek to deliver an “artificial pancreas” experience in the near future, making diabetes care more streamlined and less burdensome than ever before. Advancements in diabetes technology present living with the disease in an increasingly hopeful light.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
About Author - Ravina Pandya
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals. LinkedIn Profile
